Revenue of anti-diabetes drugs MENA 2016-2028

Revenue of anti-diabetes drugs in the Middle East and North Africa region from 2016 to 2028

Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G). 

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats
Use Statista now: unlimited access to all content

Statistics on " Diabetes in the Middle East and North Africa region "

Other statistics that may interest you Diabetes in the Middle East and North Africa region

Global overview

7

Prevalence of diabetes in MENA

6

Prevalence of obesity in MENA

8

Diabetes medication and spending in MENA

7
Use Statista now: unlimited access to all content
Learn more about how Statista can support your business.